Browsing Tag
CTI Life Sciences Fund
1 post
Thryv Therapeutics secures FDA IND clearance to launch first potential drug for Long QT syndrome
Thryv Therapeutics gains FDA IND clearance for THRV-1268 in Long QT Syndrome, aiming to pioneer the first disease-modifying therapy for this rare disorder.